• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
LIU Yali,DU Jiayi,SONG Wen,SUN Hao,ZHANG Xiaomin.Mechanism study of Semaglutide combined with Levetiracetam in improving neuroinflammation in epileptic lactating mice[J].Journal Of Pharmaceutical Research,2026,45(5):502-509[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 1607times   Download 730次 QR Code for this article
Scan with your phone!
GLP-1受体激动剂司美格鲁肽联合左乙拉西坦改善癫痫乳鼠神经炎症的机制
刘亚丽1,杜佳怡2,宋雯1,孙浩1,张晓敏2
Font:Larger+|Default|Smaller-
(1.山西省儿童医院儿内综合病区,山西 太原 030001;2.山西医科大学第二医院神经内科,山西 太原 030001)
摘要:
目的 神经炎症是小儿癫痫难治化的重要病理机制,靶向炎症通路成为潜在治疗策略。本研究探讨胰高血糖素样肽-1(GLP-1)受体激动剂司美格鲁肽(Semaglutide, SEM)联合抗癫痫药左乙拉西坦(Levetiracetam, LEV)对神经炎症的调控机制。方法 本研究使用网络药理学筛选司美格鲁肽左乙拉西坦治疗小儿癫痫的潜在作用靶点,并使用动物实验验证网络药理学结论。结果 通过整合网络药理学与动物实验,筛选出小儿癫痫与SEM的29个共靶基因,其中神经降压素受体1被鉴定为关键枢纽基因。在氯化锂-匹罗卡品诱导的癫痫乳鼠模型中,SEM与LEV单药治疗均显著下调海马组织神经降压素受体1(NTSR1)表达,双药联用呈现协同效应。SEM与LEV双药联用可以改善癫痫乳鼠模型行为学。SEM显著降低TNF-α、IL-1β、IL-6等炎症因子水平,富集分析证实其通过TNF信号通路改善神经炎症。结论 SEM通过抑制NTSR1表达调控神经炎症通路,增强LEV的抗癫痫神经保护作用,为临床联合用药提供新机制依据。
关键词:  司美格鲁肽  左乙拉西坦  小儿癫痫  癫痫乳鼠  神经降压素受体1  神经炎症  网络药理学
DOI:10.13506/j.cnki.jpr.2026.05.004
基金项目:山西省高等学校科技创新计划项目(No.2022L156);山西省科学技术厅基础研究计划(自由探索类)青年项目(No.202503021212352)
Received Date:January 22, 2026   Revision Date:February 09, 2026   Publication Date:May 29, 2026
Mechanism study of Semaglutide combined with Levetiracetam in improving neuroinflammation in epileptic lactating mice
LIU Yali1,DU Jiayi2,SONG Wen1,SUN Hao1,ZHANG Xiaomin2
(1.Comprehensive Pediatric Internal Medicine Ward,Shanxi Children's Hospital,Taiyuan 030001,China;2.Department of Neurology,The Second Hospital of Shanxi Medical University, Taiyuan 030001,China)
Abstract:
Objective Neuroinflammation is a key pathological mechanism underlying refractory epilepsy in children, making targeting inflammatory pathways a potential therapeutic strategy. This study investigates the regulatory mechanism of neuroinflammation by the GLP-1 receptor agonist Semaglutide (SEM) in combination with the antiepileptic drug Levetiracetam (LEV). Methods Network pharmacology was employed to identify potential target genes for SEM-LEV therapy in pediatric epilepsy, with animal experiments validating these findings. Results Integrating network pharmacology and animal studies identified 29 common target genes between pediatric epilepsy and SEM, with neuropeptide Y receptor 1 (NTR1) identified as a key hub gene. In a lithium chloride-pirocarperide-induced epileptic suckling mouse model, both SEM and LEV monotherapy significantly downregulated hippocampal NTSR1 expression, while combination therapy exhibited synergistic effects. The SEM-LEV combination improved behavioral outcomes in the epileptic suckling mouse model. SEM significantly reduced inflammatory mediators including TNF-α, IL-1β, and IL-6, with enrichment analysis confirming its enhancement of neuroinflammation mitigation via the TNF signaling pathway.Conclusion SEM modulates neuroinflammatory pathways by suppressing NTSR1 expression, thereby amplifying LEV's antiepileptic neuroprotective effects and providing novel mechanistic evidence for clinical combination therapy.
Key words:  Semaglutide  Levetiracetam  Pediatric epilepsy  Epileptic lactating mice  NTSR1  Neuroinflammation  Network pharmacology
Today's Visits:447    Total Visits:2383131
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.